May 15, 2025

Catalyst is pleased to attend the FDLI 2025 Annual Conference, where leaders from across the healthcare environment come together to discuss the most pressing issues in food and drug law.

We’re especially looking forward to hearing Dr. Ellen Sigal’s remarks as she receives the prestigious Dr. Harvey W. Wiley FDAAA Award – one of FDLI’s highest honors. Named after the first commissioner of the US Food and Drug Administration, the award recognizes individuals who have made outstanding contributions to promoting public health and advancing FDA’s regulatory mission.

As Chairperson and founder of Friends of Cancer Research, Dr. Sigal has been a driving force behind transformative policy and regulatory initiatives that accelerate access to life-saving treatments. Her leadership spans influential roles at NIH, PCORI, the Reagan-Udall Foundation, and the Cancer Moonshot initiative, among many others.

Congratulations, Dr. Sigal!

If you are attending the FDLI conference, we would love to chat - reach out to us on LinkedIn!

Thank you! Your submission has been received!

Download file

Oops! Something went wrong while submitting the form.

Recent News

NEW WHITE PAPER: Data-Informed Optimization of CAR T-Cell Therapy Long-Term Follow-Up (Preprint)

Multistakeholder collaboration, led by Catalyst Healthcare Consulting, to Recommend Data-Informed Optimization of CAR T-Cell Therapy Long-Term Follow-Up (preprint).

Catalyst, in collaboration with the Emily Whitehead Foundation, publishes Amplifying the Voice of CAR T-Cell Therapy Patients and Caregivers

Understanding the patient experience with CAR-T long-term follow-up (LTFU) is essential for building a sustainable model. Catalyst...

Recent blogs

Nancy Myers to speak at 4th Agentic AI Innovation Summit at #JPM26 conference.

Catalyst’s Nancy Myers is looking forward to speaking on a panel at the 4th Agentic AI Innovation Summit on January 12 at 11 am. She will speak alongside Vada A. Perkins, Andrew Robertson, Jimita Parekh, and moderator Brad Pryde. If you are attending, we would love to chat – reach out to us on LinkedIn!

Nancy Myers Speaks on Better Leveraging Existing Knowledge During OTP Public Listening Meeting

Catalyst CEO, Nancy Myers, had the opportunity to address CBER leadership during OTP’s September 18th public listening meeting titled “Leveraging Knowledge for Facilitating the Development and Review of Cell and Gene Therapies.” Though a PDUFA VII commitment and a required action, meetings like this one provide a critical space for industry and the Agency to share ideas and deliver better outcomes for patients.

Plan for Consolidating FDA’s Adverse Event Reporting Systems: Good Idea but Easier Said than Done

May 15, 2025

Recent News

NEW WHITE PAPER: Data-Informed Optimization of CAR T-Cell Therapy Long-Term Follow-Up (Preprint)

Catalyst, in collaboration with the Emily Whitehead Foundation, publishes Amplifying the Voice of CAR T-Cell Therapy Patients and Caregivers

Recent blogs

Nancy Myers to speak at 4th Agentic AI Innovation Summit at #JPM26 conference.

Nancy Myers Speaks on Better Leveraging Existing Knowledge During OTP Public Listening Meeting

Plan for Consolidating FDA’s Adverse Event Reporting Systems: Good Idea but Easier Said than Done

Sitemap

Newsletter